Eli Lilly and Company (LLY) has filed lawsuits against six entities, including peptide suppliers, medical spas, and compounding pharmacies, for distributing unapproved retatrutide in the United States, starting in August 2026. Retatrutide (LY3437943), a once-weekly subcutaneous injection currently in Phase 3 clinical trials, is a triple-acting receptor agonist that stimulates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors. The product has not been approved by any regulatory agency. Therefore, the products sold are not manufactured or tested by Lilly. The lawsuits aim to control patent infringement, false advertising, trademark violations, and potential patient safety risks, serving as a pre-commercialization defense measure.

The Phase 3 TRIUMPH-4 trial, which evaluated retatrutide in patients with knee osteoarthritis and obesity, showed that the 12mg group achieved an average weight reduction of 28.7% and 32.3 kg over 68 weeks, compared to 2.1% in the placebo group. The TRIUMPH-2 and TRIUMPH-3 trials, released in July 2026, also met their primary weight loss endpoints. Lilly plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first quarter of 2027.

Lilly has also reported over 200 retatrutide distributors to the FDA and requested that payment and shipping providers block transactions with these entities. In March 2026, the FDA issued a warning letter to Gram Peptides regarding the sale of retatrutide in the United States. Adverse events associated with products that differ in ingredient content, sterility, and storage conditions from the clinical trial standards could be misinterpreted as safety signals of the candidate itself, which could negatively impact patient recruitment and pre-launch brand trust. Therefore, blocking the distribution channels is an extension of regulatory compliance and pharmacovigilance.

Goldman Sachs Research estimates that the global obesity treatment market will reach $95 billion in 2030, highlighting the significant commercial potential of retatrutide. Currently, the U.S. market includes Novo Nordisk's (NVO) Wegovy (semaglutide, a GLP-1 receptor agonist, approved by the FDA in 2021) and Lilly's Zepbound (tirzepatide, a dual GIP/GLP-1 receptor agonist, approved by the FDA on November 8, 2023). Novo Nordisk's late-stage CagriSema, currently in Phase 3 clinical trials, is a combination of cagrilintide and semaglutide. Retatrutide's 28.7% weight loss result raises the bar for efficacy in this competitive landscape. This lawsuit is a measure to control the supply chain and brand usage before sales begin, in order to protect the price, quality, and distribution exclusivity of the approved product in the future.